Design and Synthesis of a Tetrahydroisoquinoline‐Based Hydroxamate Derivative (ZYJ‐34v), An Oral Active Histone Deacetylase Inhibitor with Potent Antitumor Activity

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Chemical Biology and Drug Design

• Publication date

  2013-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/cbdd.12144PMID 23581848PMCID PMC3723752
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives.

  2012cited by this paper
• A novel class of small molecule inhibitors of HDAC6.

  2012cited by this paper
• Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.

  2011cited by this paper
• Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities.

  2011cited by this paper
• Short-Chain HDAC Inhibitors Differentially Affect Vertebrate Development and Neuronal Chromatin

  2011influential reference
• Discovery of N-hydroxy-4-(3-phenylpropanamido)benzamide derivative 5j, a novel histone deacetylase inhibitor, as a potential therapeutic agent for human breast cancer

  2011cited by this paper
• Chemical Phylogenetics of Histone Deacetylases

  2010cited by this paper
• Epigenetic opportunities and challenges in cancer.

  2010influential reference
• Effect of Inhibiting Histone Deacetylase with Short-Chain Carboxylic Acids and Their Hydroxamic Acid Analogs on Vertebrate Development and Neuronal Chromatin.

  2010cited by this paper
• Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors.

  2010cited by this paper
• HDAC family: What are the cancer relevant targets?

  2009cited by this paper
• Acetylation and deacetylation of non-histone proteins.

  2005cited by this paper
• Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1

  2005cited by this paper
• Histone acetylases and deacetylases in cell proliferation.

  1999cited by this paper
• Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs.

  1997cited by this paper
• Histone Deacetylase--A Regulator of Transcription

  1996influential reference

• 1,2,3,4-Tetrahydroisoquinoline (THIQ) as privileged scaffold for anticancer de novo drug design

  2021cites this paper
• C-H Bond Functionalization of Tetrahydropyridopyrimidines and Other Related Hetereocycles.

  2017cites this paper
• Design, synthesis, and biological characterization of tamibarotene analogs as anticancer agents

  2016cites this paper
• Design of dual MMP-2/HDAC-8 inhibitors by pharmacophore mapping, molecular docking, synthesis and biological activity

  2015cites this paper
• Novel strategies for catalytic asymmetric synthesis of C1-chiral 1,2,3,4-tetrahydroisoquinolines and 3,4-dihydrotetrahydroisoquinolines

  2015cites this paper